Relay is handing off exclusive global development and commercialization rights for lirafugratinib, a fibroblast growth factor ...

This International Day of Persons with Disabilities IDPD know more about Achondroplasia Also find out about its cure ...

Relay Therapeutics (RLAY) and Elevar Therapeutics announced an exclusive global licensing agreement for lirafugratinib. Lirafugratinib is a ...

Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

Relay Therapeutics faces challenges with limited clinical data and high expenses but shows promise with their 4D drug design ...

The webcast of the fireside chat will be accessible in the investor section of 89bio's website. A replay of the webcast will ...

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego.

Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the drug.

Discovered in-house by Eisai’s Tsukuba Research Laboratories, TASFYGO is an orally available novel tyrosine kinase inhibitor ...

Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 ...

Researchers at University of Tsukuba have found that the phosphate concentration in proximal tubule fluid, estimated from ...